Skip to main content

Table 1 Tau-reducing compounds identified from initial in-cell western screening assay

From: Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression

Functional Grouping

Drug Name

Tau IR as a % Of Vehicle Control

GAPDH IR as a % Of Vehicle Control

Aggregation inhibitors

Daunorubicin

21 ± 0

52 ± 6

 

Diazaquone

66 ± 3

106 ± 6

 

Methylene Blue

72 ± 6

112 ± 6

 

EPICATECHIN

100 ± 4

140 ± 5

 

Doxorubicin HCl

41 ± 3

56 ± 6

Antibiotics

Alexidine HCl

57 ± 0

91 ± 9

 

Gramicidin

58 ± 0

84 ± 0

 

Ciclopirox

81 ± 2

109 ± 6

Anti-proliferatives

Camptothecine

38 ± 0

71 ± 1

 

Azacytidine-5

40 ± 0

56 ± 3

 

Emetine diHCl

51 ± 11

69 ± 2

 

Mycophenolic Acid

77 ± 0

100 ± 7

 

Azaguanine-8

79 ± 0

88 ± 3

Microtubule regulators

Paclitaxel

47 ± 2

61 ± 4

 

Colchicine

44 ± 0

93 ± 6

 

Albendazole

44 ± 4

93 ± 12

 

Podophyllotoxin

37 ± 0

63 ± 2

 

Nocodazole

38 ± 0

61 ± 3

 

Mebendazole

45 ± 3

69 ± 4

 

Fenbendazole

51 ± 2

76 ± 9

 

Chelidonine

67 ± 0

96 ± 4

 

Rotenone

72 ± 0

99 ± 1

Receptor Antagonists

Lanotoside C

61 ± 2

79 ± 2

 

Lasalocid Na salt

77 ± 2

96 ± 2

Steroids

BETAMETHASONE

99 ± 0

146 ± 13

 

Norethindrone

69 ± 1

110 ± 3

  1. Italics = Drugs that reduced tau levels, but that reduced GAPDH levels by >25% indicating some toxicity; SMALL CAPS = Drugs that increased GAPDH levels without reducing tau levels; Bold = Drugs resulting in >25% reductions in tau levels with <10% reductions in GAPDH levels; Bold Italics= Drugs demonstrating <25% reductions in tau levels and/or 10–25% changes in GAPDH levels. IR indicates immunoreactivity. SD indicates standard deviation. Compounds are grouped based on their functional class.